| Abstract | BACKGROUND: Metastatic uterine cancer is notoriously difficult to treat, presenting a poor prognosis and a median survival time of less than 1 year. We present the successful use of the antiestrogen fulvestrant in an endocrine therapy-naive patient with advanced uterine cancer. CASE REPORT: A 64-year-old female presented with advanced uterine cancer 7.0 x 6.0 x 5.5 cm in size, with infiltration of the bladder. Previous chemotherapy and radiotherapy had been unsuccessful in preventing disease progression, and the patient developed hepatic metastases. As the tumor expressed a high level of estrogen receptor, treatment with fulvestrant 250 mg/month was initiated. RESULTS: 25 months after commencing fulvestrant treatment, the tumor had decreased in size to 4.8 x 3.5 x 3.2 cm, and the hepatic metastases were no longer detectable. Throughout treatment, the patient maintained a Karnofsky performance index of 90%. CONCLUSION: We suggest that fulvestrant may be an active and well-tolerated treatment option for patients with estrogen receptor- positive advanced uterine cancer. |
| Authors | Michael P Lux, Evelyn M Wenkel, Kai Beckmann, Matthias W Beckmann, Falk Thiel
(Affiliation: Department of Obstetrics and Gynecology, Universitätsklinikum Erlangen, Germany. michael.lux at gyn.imed.uni-erlangen.de)
|
| Journal | Onkologie
(Onkologie)
Vol. 29
Issue 12
Pg. 577-80
(Dec 2006)
ISSN: 0378-584X Switzerland |
| PMID | 17202829
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
| Chemical References |
- Antineoplastic Agents, Hormonal
- Receptors, Estrogen
- fulvestrant
- Estradiol
|
| Topics |
- Antineoplastic Agents, Hormonal
(therapeutic use)
- Estradiol
(analogs & derivatives, therapeutic use)
- Female
- Humans
- Liver Neoplasms
(blood, drug therapy, secondary)
- Middle Aged
- Receptors, Estrogen
(blood)
- Treatment Outcome
- Urinary Bladder Neoplasms
(blood, drug therapy, secondary)
- Uterine Neoplasms
(drug therapy)
|
